- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07787949
Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects
Evaluation of Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects: A Randomized Clinical Trial
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Periodontitis is a multifactorial inflammatory disease that occurs due to the challenge between the host response and specific periodontal pathogens, leading to a gradual destruction of the periodontal supporting tissues over time.
Different regenerative approaches have been proposed including guided tissue regeneration (GTR); bone grafts, bioactive agents such as enamel matrix derivative (EMD) and platelet concentrates.
Using the minimally invasive nonsurgical technique (MINST) implements magnification with microscope/loupes and delicate instruments, to perform the periodontal debridement with more effective root debridement and less soft tissue trauma. MINST significantly improve the visualization and root decontamination, and at the same time preserve the gingival margin and consequently improve the aesthetic results and tissue stability.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Moustafa A Ahmed, B.D.S
- Numéro de téléphone: 00201098378998
- E-mail: 23110295.pg@o6u.edu.eg
Lieux d'étude
-
-
Giza Governorate
-
Giza, Giza Governorate, Egypte, 12511
- Recrutement
- October 6 University (Faculty of Dentistry)
-
Sous-enquêteur:
- Reham L Aggour, MD
-
Contact:
- Moustafa A Ahmed, B.D.S
- Numéro de téléphone: 00201098378998
- E-mail: 23110295.pg@o6u.edu.eg
-
Sous-enquêteur:
- Shereen F Ahmed, MD
-
Sous-enquêteur:
- Wessam I Shehab, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patients of both genders >18 years old, medically free of systemic diseases affecting periodontal regeneration.
- Diagnosis of stage III, grade B periodontitis (according to the AAP/EFP classification 2018) with the presence of class II furcation defect in either the maxillary (buccal) or mandibular arch (buccal or lingual) as determined by clinical evaluation and confirmed by radiographic evaluation.
- Gingival margin and interdental bone positioned coronally to the furcation entrance.
- Commitment to maintenance visits and follow-up.
- Absence of primary endodontic lesions.
Exclusion Criteria:
- Patients suffering from any systemic diseases that may affect the outcome of periodontal therapy, including diabetes, immune deficiencies, etc;
- Patients that received periodontal surgical treatments in the past 12 months.
- Smoking (current or in past 5 years)
- Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months prior to periodontal therapy.
- Pregnant and lactating females.
- Teeth with hopeless prognosis
- Third molars
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Positive control group
Patients will receive minimally invasive non-surgical technique (MINST) alone
|
Patients will receive minimally invasive non-surgical technique (MINST) alone
|
|
Expérimental: Test group
Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection
|
Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Radiographic Bone Fill at the Furcation Site
Délai: 6 months after treatment
|
Radiographic bone fill at the furcation site will be assessed using cone-beam computed tomography (CBCT).
The analysis will include measurement of the filled bone volume (FBV) at the furcation area using segmentation.
|
6 months after treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Horizontal Clinical Attachment Level
Délai: 6 months after treatment
|
Horizontal clinical attachment level will be assessed using periodontal probing at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Vertical Clinical Attachment Level
Délai: 6 months after treatment
|
Vertical clinical attachment levels will be assessed using periodontal probing at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Probing Pocket Depth
Délai: 6 months after treatment
|
Probing pocket depth (PPD) will be measured in millimeters from the gingival margin to the base of the periodontal sulcus at six sites per tooth using a UNC-15 periodontal probe.
Measurements will be recorded at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Gingival Margin Location
Délai: 6 months after treatment
|
The location of the gingival margin will be assessed by measuring the distance from the cemento-enamel junction (CEJ) to the gingival margin.
Measurements will be recorded at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Plaque Index
Délai: 6 months after treatment
|
Plaque index (PI) will be assessed to evaluate oral hygiene status by measuring dental plaque accumulation in areas adjacent to the gingival margin.
Plaque index will be recorded at baseline and 6 months after treatment.
|
6 months after treatment
|
|
Change in Bleeding on Probing
Délai: 6 months after treatment
|
Bleeding on probing (BoP) will be assessed by gently inserting a periodontal probe into the gingival sulcus at the base of the interdental papilla and recording the intensity of bleeding after a short delay.
BoP will be assessed at baseline and 6 months after treatment.
|
6 months after treatment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 23110295
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .